125 Results for "

BAF3

" in MedChemExpress (MCE) Product Catalog:
Products (125)

125 Results for "BAF3" in MCE Product Catalog:

24
24 Publications Verification
Cat. No.: HY-15306
CAS No.: 496775-61-2
Purity:  99.94%
Synonyms: SB-497115
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well [3] .
loading...
    loading...
24
24 Publications Verification
Cat. No.: HY-15306A
CAS No.: 496775-62-3
Purity:  99.96%
Synonyms: Eltrombopag diethanolamine salt; SB-497115GR
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well [3] .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-104010
CAS No.: 1492952-76-7
Purity:  99.61%
Synonyms: ABL001
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-104010A
CAS No.: 2119669-71-3
Purity:  99.84%
Synonyms: ABL001 hydrochloride
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-153724
CAS No.: 2937327-93-8
Purity:  99.65%
Target:  

Ras

Research Areas:  

Cancer

BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-18960
CAS No.: 1895895-38-1
Target:  

JAK

Research Areas:  

Cancer

CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13491
CAS No.: 1033769-28-6
Purity:  99.44%
Target:  

Trk Receptor

Research Areas:  

Cancer

GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC50 values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-11007
CAS No.: 778270-11-4
Purity:  99.82%
Research Areas:  

Cancer

GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-125845
CAS No.: 1448297-52-6
Purity:  99.09%
Synonyms: VH032-NH2; VHL ligand 1
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-157229
CAS No.: 2765525-82-2
Purity:  98.25%
Target:  

EGFR ERK

Research Areas:  

Cancer

STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109020
CAS No.: 1229453-99-9
Purity:  99.84%
Synonyms: LHA510
Target:  

VEGFR

Research Areas:  

Others

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119944
CAS No.: 2260886-64-2
Purity:  99.78%
Target:  

EGFR

Research Areas:  

Cancer

JND3229 is a reversible EGFR C797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFR L858R/T790M/C797S, EGFR WT and EGFR L858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma .
loading...
    loading...
Cat. No.: HY-129550
CAS No.: 2664214-60-0
Purity:  99.28%
Target:  

EGFR

Research Areas:  

Cancer

BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties .
loading...
    loading...
Cat. No.: HY-131906
CAS No.: 2593402-36-7
Purity:  99.15%
Target:  

JAK FLT3 Apoptosis

Research Areas:  

Cancer

JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .
loading...
    loading...
Cat. No.: HY-125834
CAS No.: 2490599-18-1
Purity:  98.69%
GMB-475 is a potent BCR-ABL1 PROTAC based on Von Hippel-Lindau (VHL). GMB-475 targets the nutmeg pocket of ABL1 in an ectopic manner and degrades BCR-ABL1 protein through the ubiquitin proteasome pathway. GMB-475 inhibits the proliferation of human K562 cells and mouse Ba/F3 cells, and is used for the study of chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-134877
CAS No.: 2311901-93-4
Purity:  99.88%
Target:  

EGFR ERK Akt

Research Areas:  

Cancer

BAY 2476568 is a potent and mutant-selective inhibitor targeting EGFR exon20 insertion variants. BAY 2476568 potently inhibits the kinase activity of EGFR exon20 insertion mutants (insASV, insSVD, insNPG) with IC50 values of 0.09 nM, 0.21 nM, and 0.11 nM, respectively. BAY 2476568 inhibits EGFR (Y1068) phosphorylation and reduces the phosphorylation of ERK1/2 and Akt (S473) in Ba/F3 cells expressing EGFR exon20 insertion mutants (insASV, insSVD). BAY 2476568 can be used for the study of non-small cell lung cancer (NSCLC) driven by EGFR exon20 insertion mutations .
loading...
    loading...
Cat. No.: HY-123450
CAS No.: 1257628-57-1
Purity:  99.60%
Target:  

Bcr-Abl Apoptosis PDGFR

Research Areas:  

Cancer

S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies [3]. S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-139997
CAS No.: 2140806-84-2
Target:  

PROTACs EGFR

Research Areas:  

Cancer

DDC-01-163 is an allosteric PROTAC degrader targeting EGFR. DDC-01-163 is dependent on the ubiquitin–proteasome system. DDC-01-163 can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells. DDC-01-163 is effective against Osimertinib (HY-15772)-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations. DDC-01-163 exhibits enhanced anti-proliferative activity against L858R/T790M EGFR-Ba/F3 cells when combined with the ATP-site EGFR inhibitor Osimertinib. DDC-01-163 can be used for the study of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-121852
CAS No.: 447459-51-0
Purity:  98.85%
Synonyms: SCH-225336
Target:  

Cannabinoid Receptor

Research Areas:  

Inflammation/Immunology

SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice .
loading...
    loading...
Cat. No.: HY-161633
CAS No.: 3034244-71-5
Target:  

PROTACs EGFR FAK

Research Areas:  

Cancer

PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC50 <100 nM. PROTAC EGFR degrader 11 binds CRBN-DDB1 with a Ki of 36 nM. PROTAC EGFR degrader 11 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC50 <100 nM.
loading...
    loading...